PDS Biotechnology CorporationPDSBNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank62
3Y CAGR-8.2%
5Y CAGR+16.7%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-8.2%/yr
vs +83.9%/yr prior
5Y CAGR
+16.7%/yr
Recent deceleration
Acceleration
-92.1pp
Decelerating
Percentile
P62
Within normal range
vs 5Y Ago
2.2x
Strong expansion
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$32.21M-11.2%
2024$36.26M-15.8%
2023$43.05M+3.3%
2022$41.67M+94.4%
2021$21.44M+43.9%
2020$14.90M-3.3%
2019$15.41M+322.7%
2018$3.65M-93.0%
2017$51.97M+31.5%
2016$39.51M-